Search
Immunoprecise Antibodies Ltd
IPAAdd to Watchlist
2.070USD
0.0000.00%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
95.54MMarket Cap
LossP/E TTM
More Details of Immunoprecise Antibodies Ltd Company
ImmunoPrecise Antibodies Ltd. is a biotechnology company that leverages multi-omics modeling and complex artificial intelligence through a series of proprietary and patented technologies. The Company owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies. It has several subsidiaries in North America and Europe including entities, such as Talem Therapeutics LLC, BioStrand BV, ImmunoPrecise Antibodies (Canada) Ltd. and ImmunoPrecise Antibodies (Europe) B.V. (collectively, the IPA Family). Its Contract Research Organizations (CRO) services include B cell Select; Phage Display; DeepDisplay; Abthena Bispecifics; LucinaTech Humanization; Affinity Maturation; Immunization, hybridoma, sequencing; rPEx protein manufacturing, and Cell line development. The Company utilizes custom antigen modeling, target analysis using Natural Language Processing and the HYFTTM analysis to lay the groundwork for the subsequent experimental phases.
Immunoprecise Antibodies Ltd Info
Ticker SymbolIPA
Company nameImmunoprecise Antibodies Ltd
IPO dateJan 30, 1987
CEODr. Jennifer Lynne Bath, Ph.D.
Number of employees- -
Security typeOrdinary Share
Fiscal year-endJan 30
AddressIndustrious 823 Congress Ave Suite 300
CityAUSTIN
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code78701
Phone16048060626
Websitehttps://www.ipatherapeutics.com/
Ticker SymbolIPA
IPO dateJan 30, 1987
CEODr. Jennifer Lynne Bath, Ph.D.
Company Executives of Immunoprecise Antibodies Ltd
Name
Name/Position
Position
Shareholding
Change
Dr. Jennifer Lynne Bath, Ph.D.
Dr. Jennifer Lynne Bath, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
498.12K
--
Dr. Kamil Isaev
Dr. Kamil Isaev
Independent Director
Independent Director
3.19K
--
Mr. Dirk Witters
Mr. Dirk Witters
Independent Director
Independent Director
1.95K
--
Ms. Kari Graber
Ms. Kari Graber
Vice President - Commercial Services
Vice President - Commercial Services
700.00
--
Mr. Jonathan I. (Jon) Lieber
Mr. Jonathan I. (Jon) Lieber
Director
Director
--
--
Mr. Joseph Scheffler
Mr. Joseph Scheffler
Interim Chief Financial Officer
Interim Chief Financial Officer
--
--
Dr. Shuji Sato
Dr. Shuji Sato
Vice President - Innovative Solutions
Vice President - Innovative Solutions
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Jennifer Lynne Bath, Ph.D.
Dr. Jennifer Lynne Bath, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
498.12K
--
Dr. Kamil Isaev
Dr. Kamil Isaev
Independent Director
Independent Director
3.19K
--
Mr. Dirk Witters
Mr. Dirk Witters
Independent Director
Independent Director
1.95K
--
Ms. Kari Graber
Ms. Kari Graber
Vice President - Commercial Services
Vice President - Commercial Services
700.00
--
Mr. Jonathan I. (Jon) Lieber
Mr. Jonathan I. (Jon) Lieber
Director
Director
--
--
Mr. Joseph Scheffler
Mr. Joseph Scheffler
Interim Chief Financial Officer
Interim Chief Financial Officer
--
--
FAQs
Who are the top five shareholders of Immunoprecise Antibodies Ltd?
The top five shareholders of Immunoprecise Antibodies Ltd are: Dr. Jennifer Lynne Bath, Ph.D.
How many institutions hold shares of Immunoprecise Antibodies Ltd (IPA)?
As of 2026Q1, 47 institutions hold shares of Immunoprecise Antibodies Ltd, with a combined market value of approximately 4.54M, accounting for 9.73% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 212280.00.
What is the biggest source of revenue for Immunoprecise Antibodies Ltd?
In 2026Q1, the Project revenue business generated the highest revenue for Immunoprecise Antibodies Ltd, amounting to 4.11M and accounting for 98.85% of total revenue.